Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial

Plain-language guide to PMID 32843370 (2020): double-blind randomized controlled trial study of Somatostatin and Pasireotide.

Key Facts

PMID: 32843370
Journal: Clinical journal of the American Society of Nephrology : CJASN
Year: 2020
Study type: Randomized Controlled Trial
Authors: Hogan MC et al. (15 authors)
DOI: 10.2215/CJN.13661119

What This Study Did, in Plain Language

What Was Tested

Researchers studied Somatostatin and Pasireotide in this randomized controlled trial publication.

Pasireotide LAR in Severe Polycystic Liver Disease, NCT01670110 PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_08_28_CJN13661119.mp3.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Somatostatin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Somatostatin group a baseline to be compared against.

Individuals with severe polycystic liver disease were assigned in a 2:1 ratio in a 1-year, double-blind, randomized trial to receive pasireotide long-acting release or placebo.

Primary outcome was change in total liver volume; secondary outcomes were change in total kidney volume, eGFR, and quality of life.

What Was Measured

The subject headings attached to it are Cysts, Disease Progression, Glomerular Filtration Rate, Kidney, Liver, Liver Diseases and Minnesota.

Author keywords: hepatic cyst, polycystic kidney disease and somatostatin analog.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Pasireotide.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.

Our Notes on the Compounds

Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.

Pasireotide: An FDA-approved multi-receptor somatostatin analog for Cushing's disease and acromegaly; high blood sugar is a common side effect.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.